| Antibacterial natural products in medicinal chemistry—exodus or revival? F Von Nussbaum, M Brands, B Hinzen, S Weigand, D Häbich Angewandte Chemie International Edition 45 (31), 5072-5129, 2006 | 881 | 2006 |
| Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction RC Hillig, B Sautier, J Schroeder, D Moosmayer, A Hilpmann, ... Proceedings of the National Academy of Sciences 116 (7), 2551-2560, 2019 | 323 | 2019 |
| Antibakterielle Naturstoffe in der medizinischen Chemie–Exodus oder Renaissance? F von Nussbaum, M Brands, B Hinzen, S Weigand, D Häbich Angewandte Chemie 118 (31), 5194-5254, 2006 | 179 | 2006 |
| A rapid total synthesis of spirotryprostatin B: proof of its relative and absolute stereochemistry F von Nussbaum, SJ Danishefsky Angewandte Chemie International Edition 39 (12), 2175-2178, 2000 | 160 | 2000 |
| The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage–inducing or repair–compromising therapies in preclinical cancer models AM Wengner, G Siemeister, U Lücking, J Lefranc, L Wortmann, P Lienau, ... Molecular cancer therapeutics 19 (1), 26-38, 2020 | 151 | 2020 |
| Identification of atuveciclib (BAY 1143572), the first highly selective, clinical PTEFb/CDK9 inhibitor for the treatment of cancer U Lücking, A Scholz, P Lienau, G Siemeister, D Kosemund, R Bohlmann, ... ChemMedChem 12 (21), 1776-1793, 2017 | 140 | 2017 |
| Neutrophil elastase inhibitors for the treatment of (cardio) pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores F von Nussbaum, VMJ Li Bioorganic & medicinal chemistry letters 25 (20), 4370-4381, 2015 | 105 | 2015 |
| Novel Mps1 kinase inhibitors with potent antitumor activity AM Wengner, G Siemeister, M Koppitz, V Schulze, D Kosemund, U Klar, ... Molecular cancer therapeutics 15 (4), 583-592, 2016 | 104 | 2016 |
| Platensimycin, a new antibiotic and “superbug challenger” from nature D Häbich, F von Nussbaum ChemMedChem: Chemistry Enabling Drug Discovery 1 (9), 951-954, 2006 | 100 | 2006 |
| Stephacidin B—a new stage of complexity within prenylated indole alkaloids from fungi F von Nussbaum Angewandte Chemie International Edition 42 (27), 3068-3071, 2003 | 91 | 2003 |
| Freezing the bioactive conformation to boost potency: The identification of BAY 85‐8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases F von Nussbaum, VMJ Li, S Allerheiligen, S Anlauf, L Bärfacker, ... ChemMedChem 10 (7), 1163-1173, 2015 | 71 | 2015 |
| Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524 AP Baron, C von Schubert, F Cubizolles, G Siemeister, M Hitchcock, ... Elife 5, e12187, 2016 | 64 | 2016 |
| An Iron(III)–Catechol Complex as a Mushroom Pigment F von Nussbaum, P Spiteller, M Rüth, W Steglich, G Wanner, B Gamblin, ... Angewandte Chemie International Edition 37 (23), 3292-3295, 1998 | 62 | 1998 |
| BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models O Politz, F Siegel, L Bärfacker, U Bömer, A Hägebarth, WJ Scott, ... International journal of cancer 140 (2), 449-459, 2017 | 56 | 2017 |
| Multiple attack on bacteria by the new antibiotic teixobactin. F von Nussbaum, RD Süssmuth Angewandte Chemie International Edition 54 (23), 2015 | 55 | 2015 |
| Structure and total synthesis of lysobactin (katanosin B) F von Nussbaum, S Anlauf, J Benet‐Buchholz, D Häbich, J Köbberling, ... Angewandte Chemie 119 (12), 2085-2088, 2007 | 53 | 2007 |
| Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo G Siemeister, A Mengel, AE Fernández-Montalván, W Bone, J Schröder, ... Clinical Cancer Research 25 (4), 1404-1414, 2019 | 50 | 2019 |
| Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in … U Lücking, L Wortmann, AM Wengner, J Lefranc, P Lienau, H Briem, ... Journal of medicinal chemistry 63 (13), 7293-7325, 2020 | 43 | 2020 |
| Synthesis of 1-(2-Aminophenyl)isoquinolines and the Biological Activity of Their cis-Dichloro Platinum(II) Complexes F von Nussbaum, B Miller, S Wild, CS Hilger, S Schumann, H Zorbas, ... Journal of medicinal chemistry 42 (18), 3478-3485, 1999 | 43 | 1999 |
| BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity S Santag, F Siegel, AM Wengner, C Lange, U Bömer, K Eis, F Pühler, ... Cancer letters 390, 21-29, 2017 | 42 | 2017 |
